IN2013CH05441A - - Google Patents
Download PDFInfo
- Publication number
- IN2013CH05441A IN2013CH05441A IN5441CH2013A IN2013CH05441A IN 2013CH05441 A IN2013CH05441 A IN 2013CH05441A IN 5441CH2013 A IN5441CH2013 A IN 5441CH2013A IN 2013CH05441 A IN2013CH05441 A IN 2013CH05441A
- Authority
- IN
- India
- Prior art keywords
- preparation
- pharmaceutical compositions
- same
- stabilized pharmaceutical
- solvates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5441CH2013 IN2013CH05441A (en) | 2013-11-26 | 2013-11-26 | |
US14/544,126 US20150157618A1 (en) | 2013-11-26 | 2014-11-26 | Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5441CH2013 IN2013CH05441A (en) | 2013-11-26 | 2013-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013CH05441A true IN2013CH05441A (en) | 2015-05-29 |
Family
ID=53270042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5441CH2013 IN2013CH05441A (en) | 2013-11-26 | 2013-11-26 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20150157618A1 (en) |
IN (1) | IN2013CH05441A (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
TR201617984A2 (en) * | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN |
JP2018104425A (en) * | 2016-12-26 | 2018-07-05 | 日本ケミファ株式会社 | Tablet containing dabigatran etexilate or a pharmaceutically acceptable salt thereof |
JP2018184375A (en) * | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same |
TR201722323A2 (en) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral pharmaceutical compositions of dabigatran |
CN110354123B (en) * | 2018-04-04 | 2023-11-24 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
CN110354122B (en) * | 2018-04-04 | 2023-07-28 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
EP3787624A4 (en) * | 2018-05-04 | 2022-03-30 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule-in-capsule compositions of dabigatran etexilate |
TR201905308A2 (en) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A CAPSULE FORMULATION OF DABIGATRAN ETEXILATE |
JP2021014411A (en) * | 2019-07-10 | 2021-02-12 | 日医工株式会社 | Stable dabigatran etexilate preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
US8821928B2 (en) * | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
BRPI0921479A2 (en) * | 2008-11-11 | 2016-01-12 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved safety profile compared to conventional warfarin therapy |
DK2542224T3 (en) * | 2010-03-01 | 2014-10-20 | Ratiopharm Gmbh | ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANETEXILATE |
-
2013
- 2013-11-26 IN IN5441CH2013 patent/IN2013CH05441A/en unknown
-
2014
- 2014-11-26 US US14/544,126 patent/US20150157618A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150157618A1 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2013CH05441A (en) | ||
MX2018013668A (en) | Inhibitors of hepatitis c virus. | |
PH12019500163A1 (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof | |
MX2015012850A (en) | Arginine methyltransferase inhibitors and uses thereof. | |
WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
IN2014MN02658A (en) | ||
MX2017008518A (en) | Isoquinoline compounds for the treatment of hiv. | |
PH12019501639A1 (en) | Jaki selective inhibitors | |
IN2014MN02245A (en) | ||
PH12016501462A1 (en) | Neprilysin inhibitors | |
MX2018004304A (en) | Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors. | |
IN2013MU03862A (en) | ||
WO2016142821A3 (en) | Compositions containing a thrombin inhibitor | |
MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
WO2014145314A3 (en) | Methods and compositions for gamma-glutamyl cycle modulation | |
WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
GEP201706675B (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
MX2019005723A (en) | Fgfr4 inhibitor and preparation method and use thereof. | |
IN2013MU03422A (en) | ||
IN2013MU03308A (en) | ||
IN2013MU03309A (en) | ||
IN2013MU03421A (en) | ||
IN2014DN07897A (en) |